Aurinia exists to make a difference. From the earliest days of the company, we’ve seen the potential in applying a creative, thoughtful and responsible approach to developing and commercializing therapies with a goal of changing the course for patients in disease areas that have been historically challenging to address.
We are currently developing voclosporin, an investigational therapy, for the treatment of lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). We are also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). And we are actively hunting for other innovative drugs which have the potential to change the lives of people with rare autoimmune and inflammatory diseases.
Our strategy leverages the skills and knowledge of our team’s extensive clinical experience in the treatment of renal diseases and autoimmune diseases, and our progress has been guided by leaders with a bold vision and expertise in principled drug development and commercialization.